Leerink Partners Cuts Price target on Diplomat Pharmacy (DPLO) Following Weak EPS Guide
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Diplomat Announces 4th Quarter and 2015 Year End Financial Results; Provides Initial 2016 Guidance
February 29, 2016 4:15 PM ESTFLINT, Mich., Feb. 29, 2016 /PRNewswire/ --Â Click here for additional information on the earnings results.Â
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter and year ended December 31, 2015. All comparisons, unless otherwise noted, are to the quarter or year ended December 31, 2014.
Fourth Quarter 2015 Highlights include:
Revenue of $987 million, an increase of 61% or $375... More